FDA Reorganization Plan Would Eliminate One ODE, Split Neuropharm Division
Executive Summary
FDA is planning to split the Division of Neuropharmacological Drug Products into two divisions - neurology and psychiatry - as part of the upcoming reorganization of the Office of New Drugs
You may also be interested in...
Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size
FDA's Office of Oncology Drug Products is undergoing a reorganization aimed at making its structure more similar to the rest of the review offices in the Center for Drug Evaluation and Research
Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size
FDA's Office of Oncology Drug Products is undergoing a reorganization aimed at making its structure more similar to the rest of the review offices in the Center for Drug Evaluation and Research
FDA Oncology Drug Reviews Headed By Justice Under Revised Structure
Deputy director of FDA's biological oncology product review team Robert Justice will head the Division of Drug Oncology Products under the reorganization of the Office of New Drugs